1294453-62-5

Basic information

• Product Name: 4-(4-bromo-3,5-dimethylphenoxy)-2-methyl-2-Butanol
• Synonyms: 4-(4-bromo-3,5-dimethylphenoxy)-2-methyl-2-Butanol
• CAS NO: 1294453-62-5
• Molecular Weight: 287.197
• Mol File: 1294453-62-5.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 4-(4-bromo-3,5-dimethylphenoxy)-2-methyl-2-Butanol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-bromo-3,5-dimethylphenoxy)-2-methyl-2-Butanol(1294453-62-5)
• EPA Substance Registry System: 4-(4-bromo-3,5-dimethylphenoxy)-2-methyl-2-Butanol(1294453-62-5)

Safety Data

• Hazardous Substances Data: 1294453-62-5(Hazardous Substances Data)

Upstream product

• 1985-88-2 4-chloro-2-methyl-2-butanol 
• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 1544739-39-0 methyl 3-(4-bromo-3,5-dimethylphenoxy)propanoate 
• 75-16-1 methylmagnesium bromide 
• 17689-66-6 3-hydroxy-3-methylbutyl toluene-4-sulfonate 
• 2568-33-4 3-methyl-butane-1,3-diol 

Downstream Products

• 1458656-71-7 2-((S)-6-((R)-7-fluoro-4-(4-(3-hydroxy-3-methylbutoxy)-2,6-dimethylphenyl)-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid 

Relevant articles and documents

PROCESS AND INTERMEDIATES FOR PREPARING GPR40 AGONISTS

The present invention relates to compounds of formula I wherein RS denotes F or CF3, Ra denotes H or C1-4-alkyl and Z denotes a leaving group or an optionally substituted or protected hydroxyl group, suitable as

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.